FDALiveFDALive.com

The World's Leading Source for FDA Broadcasting

Order Webcast

    Purchasing > Behind the Counter Availability of Certain Drugs Meeting

Single Viewer Webcast
Description: Allows for a single viewer (1 person/1 PC) to view the webcast on their desktop.

Group Webcast
Description: Allows for fullscreen viewing (1 Single Feed) for a meeting room or auditorium.

Meeting Date: 11/14/07

Price: $250.00

Meeting Date: 11/14/07

Price: $800.00

Webcast / System Compatibility Test - Please be sure to view a webcast test before purchase



System Requirements: Windows PC or MAC with Sound Card/Speakers, Windows Media Player 7 or above and A Broadband Internet Connection. Best viewed on hard-wired network unless using Wireless-N.


To download Windows Media Player click here. If you need further assistance contact FDALive Tech Support at techsupport@fdalive.com and a representative will contact you.

Upcoming Meetings

Meeting OptionsMeeting OptionsMeeting OptionsMeeting OptionsMeeting OptionsOncologic Drugs Advisory Committee

Meeting Date: 7/14/20-7/14/20

.

Meeting Details:

The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On July 14, 2020, the committee will discuss biologic license application (BLA) 761158, for belantamab mafodotin, submitted by GlaxoSmithKline Intellectual Property Development Ltd. England. The proposed indication (use) for this product is for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

 

       
Location: TelCon | Please note that due to the impact of this COVID-19 pandemic, all meeting participants will be joining this advisory committee meeting via an online teleconferencing platform. Related News Links: Not Available
Time: 9:00AM-1:30PM    
Materials:
   
       

View Meeting Details / News

Recent Meetings

Meeting OptionsMeeting OptionsMeeting OptionsPediatric Oncology Subcommittee of the ODAC (pedsODAC)

Meeting Date: 6/17/20-6/18/20

Meeting Details:

The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. On June 17, 2020, information will be presented regarding pediatric development plans for two products that are in development for an adult oncology indication. The subcommittee will consider and discuss issues relating to the development of each product for pediatric use and provide guidance to facilitate the formulation of written requests for pediatric studies, if appropriate. The two products under consideration are: (1) SP 2577 presentation by Salarius Pharmaceuticals, Inc. and (2) Marizomib, presentation by Celgene International II Sàrl, a wholly owned subsidiary of Bristol-Myers Squibb. On June 18, 2020, information will be presented regarding pediatric development plans for two products that are in development for an adult oncology indication. The subcommittee will consider and discuss issues relating to the development of each product for pediatric use and provide guidance to facilitate the formulation of written requests for pediatric studies, if appropriate. The two products under consideration are: (1) CD30.CAR-T, presentation by Tessa Therapeutics and (2) SNDX-5613, presentation by Syndax Pharmaceuticals, Inc.

 

       
Location: FDA White Oaak Related News Links: Not Available
Time: 10:00AM-3:30AM    
Materials:
   
       

View Meeting Details / News

Past Meetings

Below is a listing of all committees. Select a committee to display all meetings available for that committee.

Live Meetings

There are no Live Broadcasts available at this time.